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Abstract
Background—The World Health Organization has recommended that rotavirus (RV) vaccines be 
included in all national immunization programs as part of a strategy to control RV-associated 
diarrheal diseases. Hospital-based surveillance of RV infection is therefore crucial in monitoring 
the impact pre- and post-vaccine introduction and also to document changes in genotype 
distribution. This study sought to determine the RV genotypes circulating in the eastern region of 
Kenya before introduction of the RV vaccine.
Methods—During September 2009 to August 2011, 500 stool samples were collected from 
children <5 years of age admitted for acute diarrhea in hospitals in the eastern region of Kenya and 
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analyzed for the presence of group A RV using an enzyme immunoassay. G and P genotypes were 
determined using hemi-nested reverse transcriptase polymerase chain reaction.
Results—One hundred and eighty nine out of 500 (38%) samples analyzed were positive for 
rotavirus. The following G types were detected: G9 (50.9%), G1 (26.8%), G8 (12.1%), G12 
(3.1%), G2 (0.6%), mixed G (1.3%) and 5.1% were G nontypeable. P types detected included: 
P[8] (63.7%), P[4] (12.1%), P[6] (4.5%), mixed P (7.6%) and 12.1% were P nontypeable. The 
most dominant strain was G9P[8] (35%), followed by G1P[8] (26.8%), G8P[4] (9.6%), G12P[6] 
(2.5%), G9P[6] (1.9%), G9P[4] (1.3%), G8P[8] (1.3%), and G2P[4] (0.6%).
Conclusions—The present study demonstrates the recurring changing genotypes of RV 
circulating in Kenya, with genotypes G9, G1 and G8 being the dominant strains circulating in the 
eastern region of Kenya between 2009 and 2011. Additionally, G12 genotype was detected for the 
first time in Kenya.
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Group A rotaviruses (RVs) remain the major cause of morbidity and mortality globally and 
are associated with an estimated 453,000 deaths (range 420,000–494,000 deaths) annually in 
infants and young children <5 years of age,1 and approximately 85% of these deaths 
occurring in Sub-Saharan Africa.1,2 Infants and young children <2 years of age are most 
vulnerable to RV infection that often results in severe diarrhea and dehydration, causing 
hospitalization which can result in death.3 This age group has been the primary target of 
protection with RV vaccines, and large-scale efficacy and safety trials of 2 RV vaccines, 
Rotarix (GlaxoSmithKline, Rixensart, Belgium), containing a single human G1P[8] RV 
strain, and RotaTeq (Merck & Co., Whitehouse Station, NJ), containing 5 bovine-human 
reassortant RV strains expressing 5 human serotypes (G1, G2, G3, G4 and P[8]) have 
demonstrated the impact of these vaccines in developing countries.4–8 The recent clinical 
trials in Africa and Asia7–9 found that the vaccine significantly reduces severe diarrhea 
episodes due to RV by 48–64% during the first year of life. These vaccines have been 
reported to induce significant protection against severe diarrhea caused by homotypic and 
heterotypic RV strains4,5,10,11 and reduce childhood deaths.12 The Rotarix and RotaTeq RV 
vaccines have proved to have high efficacy in developed countries.4,6,13 Available since 
2006, these vaccines have been licensed in many countries including Kenya.14,15
The recommendation by World Health Organization (WHO) that RV vaccines be included in 
all national immunization programs, particularly in those countries where diarrheal deaths 
account for >10% of <5 mortality,16 has resulted in many countries applying for financial 
support from Global Alliance for Vaccines and Immunization to enable introduction of these 
vaccines. Based on WHO recommendations, Global Alliance for Vaccines and 
Immunization and other international partners have agreed to provide financial support for 
RV immunization in the developing world and the WHO Regional Office for Africa has been 
spearheading the sentinel surveillance of RV for the last 6 years.15 The main aim of the 
ongoing RV hospital-based surveillance studies being conducted in Africa and coordinated 
by the Regional Office for Africa of WHO is to monitor the burden of RV infection, 
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prevalence of predominant genotypes and identify unusual and emerging strains in the 
continent.15 Such studies are particularly important in countries such as Kenya that are 
considering introducing the RV vaccine in the expanded program for immunization.
RV is a non-enveloped virus with a triple-layered capsid containing 11 double-stranded 
RNA segments surrounded by 3 concentric protein layers. The outer capsid consists of VP7 
(a glycoprotein) and VP4 (a protease-sensitive protein) which carry independent 
neutralization and protective antigens.17 A binary system of RV classification has been 
established to designate the neutralization specificity of the VP7 and VP4 proteins. The VP7 
genotype is known as G and the VP4 genotype as P.17 To date, 27 different G and 35 P 
genotypes have been described in both humans and animals.18 Globally, human infections 
have been mainly caused by 5 G types (G1–G4 and G9) and 3 P types (P[4], P[6] and P[8]).
17,19,20
 Epidemiological surveillance of circulating RV strains is critical in developing 
countries to determine the protective efficacy of RV vaccines against multiple genotypes and 
to detect the eventual emergence of different strains. In Kenya, epidemiological studies have 
been done to determine the circulating RV genotypes and have showed the clinical 
importance of RV disease in young Kenyan children.15,21–24 Before the introduction and 
implementation of a universal RV vaccination program, continued monitoring of RV strain 
variations is important so that the impact of vaccination and any subsequent changes in 
circulating strains can be determined.
The main aim of this study was to determine the distribution of circulating G and P genotype 
among children <5 years of age admitted to hospitals with acute gastroenteritis in the eastern 
region of Kenya before RV vaccination introduction.
MATERIAL AND METHODS
Study Design
This study was a prospective hospital-based surveillance study in the eastern region of 
Kenya. The study was carried out in Meru General Hospital and Maua Methodist Hospital in 
Meru County. These hospitals are in close vicinity approximately 50 km apart and they both 
serve the same catchment area.
Collection of Stool Specimens
During September 2009 to August 2011, 500 fecal samples were collected from children <5 
years of age admitted with acute diarrhea in Meru General Hospital and Maua Methodist 
Hospital in the eastern region of Kenya. These hospitals were selected based on the earlier 
study by Kiulia et al (2006)21 and fulfilled requirements for RV surveillance study as 
outlined by WHO.15,25
Fecal samples and epidemiological data were collected from all children <5 years of age 
with severe nonbloody diarrhea admitted to the pediatrics ward and/or who visited the 
emergency department for treatment for acute gastroenteritis during the study period. A case 
of acute gastroenteritis was defined as the passage of ≥3 looser than normal stools within a 
24-hour period or ≥2 episodes of vomiting unexplained by other reason and as described by 
the guardian or mother at presentation to the hospital.
Kiulia et al. Page 3
Pediatr Infect Dis J. Author manuscript; available in PMC 2018 February 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
RV Detection
A 10% suspension of fresh stool in sample diluent was made and tested for the presence of 
group A RV antigen using a commercial RV antigen detection enzyme immunoassay 
(ProSpecT Rotavirus test, Oxoid, Ely, United Kingdom) according to the manufacturer’s 
instructions.
Viral RNA Extraction for Reverse Transcriptase Polymerase Chain Reaction
RV dsRNA was extracted using the QIAamp Viral RNA kit (QIAGEN GmbH, Hilden, 
Germany) according to the manufacturer’s instructions, with slight modification. Briefly, a 
10 % stool suspension was made in phosphate-buffered saline solution. The suspension was 
votexed, spinned down and supernatant used for RNA extraction. Purified extract was 
aliquoted and stored at −20°C until use.
VP7 and VP4 Genotyping of RV Strains
The VP7 and VP4 reverse transcriptase polymerase chain reaction (RT-PCR) amplification 
and genotyping were carried out as described elsewhere.26–29
Ethical Approval
This study was approved by the Kenyatta National Hospital Ethics and Research Committee 
(Number: P257/09/2008), Institutional Review committee of the Institute of Primate 
Research (Number: IRC/01/2009) and Maua Methodist Hospital Research Committee 
(MMH/08/2009). In addition, informed consent was obtained from each child’s guardians/
parents before enrolment into the study.
RESULTS
Prevalence of RV in Eastern Region
A total of 500 children with diarrhea were enrolled in the study with 189 (38%) found to be 
positive for RV infection by enzyme immunoassay.
Distribution of Circulating G and P Genotypes
Of the 189 enzyme immunoassay positive samples, 157 were randomly selected for further 
characterization by RT-PCR and they were representative of samples collected during the 
study period. Both G and P types were detected in 137/157 (87.3%) samples, while 7/157 
(4.5%) samples remained nontypeable for both G and P types (Table 1).
During the study period, the following G types were detected: G9 (50.9%), G1 (26.8%), G8 
(12.1%), G12 (3.1%) and G2 (0.6%). Mixed G types were also detected in 2 (1.3%) samples, 
and no G types were obtained in 8 samples (5.1%). The following P types were detected: 
P[8] (63.7%), P[4] (12.1%) and P[6] (4.5%). Mixed P type was found in 7.6% of samples 
and in an unexpectedly high percentage (12.1%) of samples were P nontypeable. The most 
dominant genotype was G9P[8] (35%), followed by G1P[8] (26.8%), G8P[4] (9.6%) and 
G12P[6] (2.6%). Other G and P type combinations detected were G9P[6] (1.9%), G9P[4] 
(1.3%), G8P[8] (1.3%) and G2P[4] (0.6%; Table 1). Genotypes G3 and G4 were not 
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detected in any of the samples analyzed during the study. The mixed G types detected were 
mostly G9/G12 and mixed P types were P[8] +P[4] and P[8]+P[6] (Table 1).
In this study, genotype G9 predominated throughout the entire period (Table 1). G1 was 
detected during the surveillance period 2010–2011 and G12 detected in both season 2009–
2011. G2 genotype was only found during the surveillance period 2009–2010 and then at 
very low levels (0.6%).
Age Distribution and G and P Genotypes
The age distribution of patients to the RV genotypes circulating in the eastern region of 
Kenya is shown in Table 2. RV infection was found in all the age groups at different 
frequencies. Among the globally common strains, G9P[8] and G8P[4] was found circulating 
in all age groups except in older children >25 months of age, whereas G1P[8] and G2P[4] 
were identified in younger children (7–12 months of age). G12P[6] were found circulating 
among children <24 months of age. Unusual strains and mixed infections were also found 
circulating in different age groups although at lower levels.
DISCUSSION
This study was performed to provide data on the circulating RV genotypes in the eastern 
region of Kenya, in anticipation of possible introduction of RV vaccine in the expanded 
program for immunization in Kenya. Human group A RV was detected in 37.8% of children 
hospitalized with acute gastroenteritis. This prevalence is within the range (6–56%) 
previously detected in Kenya15,22 and higher than the previous study which was carried out 
in the same region.21 The detection rate of RV in this rural setting is similar to that 
previously reported in an urban setting in 2010.15
G9 genotype was the most common genotype, followed by G1 and then G8 which is 
uncommon globally, but detected in consistently in African countries.15 The globally 
common genotype G2 was detected at lower levels in this study. This trend of G2 has also 
been documented in a study from 2002 to 2004 in the coastal region of Kenya24 and in 
another study that was done during 2000–2002 where G2 strains were detected in about 12% 
of samples.30 Over the last 8 years, no G2 has been documented in Kenya. The prevalence of 
G9 genotype was higher than that reported in the urban hospital setting in Kenya (50.9% vs. 
8%), while the prevalence of the G8 genotype was slightly lower (12.1% vs. 20%) than that 
reported in the same urban setting.5 In addition, mixed infections and nontypeable samples 
were substantially lower in the eastern region compared with previous studies (mixed 
infection with G type, 1.3% vs. 8% and G nontypeable 5.1 % vs. 28%).15,21 Genotype G9 
has been dominant over most periods in the eastern region.21 Genotype G8 is increasingly 
becoming 1 of the dominant genotypes and genotype G1 had shown an increase in this 
region of Kenya over the last 2 years. Conversely, genotype G3 and G4 that were dominant 
in the 1990s were not detected in this study.22
Recently, G12 genotypes have been increasingly detected in various countries, including in 
Africa,31,32 but have not previously been reported from Kenya.15 G12 genotypes were 
confirmed in 3.1% of samples by sequence analysis in the current study (data not shown).
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Continuous monitoring of circulating genotypes in Kenya is important, because the 
frequency of the genotypes could change over time. Seasonal shifts of RV strains in a given 
geographical region have been observed in many countries,33–36 and it is a possible 
mechanism that the virus can use to evade herd immunity and ultimately persist in that 
human population.37 Notably, this was described for G2P[4] strain in South Africa.38 The 
diversity of genotypes as found in this study may be explained by the active interaction of 
people in the region, poor environmental conditions and close contact with domesticated 
animals.
Despite the substantial strain heterogeneity detected in this study, RV vaccines have been 
shown to provide heterotypic protection against a wide range of circulating strains. For 
example, in the Rotarix clinical trials in Africa, the vaccine, which is based on an attenuated 
G1P[8] human RV strain, provided similar protection against G1 strains (64%) and non-G1 
strains (60%).8,11 However, further study on strain-specific vaccine effectiveness in settings 
like Kenya is still needed to monitor the impact of vaccines on the long-term epidemiology 
of strains in circulation. Continued monitoring of RV genotype distribution will be valuable 
to document the diversity and changes in the circulating strains that may be more important 
than ever following the introduction of RV vaccination.
Our study had some limitations; for instance, the data collected were from one regional in 
the eastern Kenya and may not generally represent the actual burden of the disease and RV 
strains circulating in the entire country or even the eastern region. However, this study builds 
on the data generated in previous surveillance studies from this region using the same 
methodology and allows a temporal trend of circulating strains to be examined. The other 
limitation was that only a proportion of the RV-positive samples (157 of 189) were 
genotyped, although they were a representative of samples collected during the study period.
In conclusion, the present study confirms the current burden of RV gastroenteritis in younger 
children and also demonstrated a high prevalence of G9, G1 and G8 strains and the absence 
of G3 and G4 in Kenya during the study period 2009–2011. From our knowledge, this is the 
first time the G12 strain is being identified in Kenya. Due to the recent emergence of G12 
RV worldwide, the findings from this study are important because they provide new 
information concerning the local and global spread of RV genotypes. Thus, continued 
monitoring and strain surveillance are important to document vaccine impact and potential 
emergence of new strains in the Kenyan community after vaccine introduction.
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TABLE 1
Distribution of RV Strains Circulating Among Children Hospitalized With Acute Gastroenteritis in the Eastern 
Region, Kenya 2009–2011
Year of Surveillance
Total Frequency (%)*
Genotype 2009–2010 2010–2011
G1P[8]   0 42 42(26.8)
G2P[4]   1   0 1(0.6)
G8P[4]   6   5 11(7.0) 
G8P[8]   0   2 2(1.3)
G8P[NT]   0   1 1(0.6)
G8P[4,8]   1   0 1(0.6)
G9P[4]   0   2 2(1.3)
G9P[6]   1   2 3(1.9)
G9P[8] 18 37 55(35.0)
G9P[NT]   0 11 11(7.0)
G9P[4,8]   0   5 5(3.2)
G9P[6,8]   3   1 4(2.5)
G12P[6]   2   2 4(2.5)
G12P[4,8]   0   1 1(0.6)
G9,12P[8]   0   1 1(0.6)
GNTP[4]   0   1 1(0.6)
GNTP[NT]   5   2 7(4.5) 
G9/12P[4,8]   0   1 1(0.6)
Total (%) 37(23.6) 120(76.4) 157(100)    
*
The percentage with respect to the total number of positive in each genotype. NT, nontypeable.
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